Gland Pharma Limited has informed the Exchange regarding a press release dated May 20, 2025, titled "Press Release on Q4 FY25 Results".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported FY25 revenue of ₹56,165 Mn, down 1% YoY, with Q4 FY25 revenue at ₹14,249 Mn (down 7% YoY but up 3% QoQ). Gross profit margin improved to 66% in Q4 FY25 from 61% a year ago, and EBITDA margin expanded by 100 bps to 24%. However, Q4 FY25 PAT fell 3% YoY to ₹1,865 Mn, and full-year PAT declined 10% YoY to ₹6,985 Mn, mainly due to losses at its European subsidiary Cenexi. The base Gland business performed well with a 38% EBITDA margin (up 100 bps), driven by US volume traction and new product launches. The board recommended a final dividend of ₹18 per share. The company also highlighted 31 new product launches in FY25, progress in biologics CDMO with Dr. Reddy's, and plans to scale up GLP-1/pen capacity from 40 million to 140 million units.
Mixed results for shareholders: improved margins and a healthy dividend are positives, but a 10% drop in full-year profit and continued losses at Cenexi may weigh on sentiment. The stock may react neutrally to negatively in the near term given the profit decline, though long-term growth bets in biologics, GLP-1s, and complex injectables could support recovery.